Evidence map›Paper›PMID 35094229›Full record

ArticleInternational ophthalmology2022

Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.

Elçin Süren, Dilek Özkaya, Ersan Çetinkaya, Mustafa Kalaycı, Kenan Yiğit, Mehmet Fatih Kücük, Muhammet Kazim Erol

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elçin SürenDepartment of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID http://orcid.org/0000-0001-8904-9828
Dilek ÖzkayaDepartment of Ophthalmology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.ORCID http://orcid.org/0000-0002-3523-8479
Ersan ÇetinkayaDepartment of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey. ersan_cetinkaya@hotmail.com.ORCID http://orcid.org/0000-0002-6876-554X
Mustafa KalaycıDepartment of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID http://orcid.org/0000-0001-8056-6634
Kenan YiğitDepartment of Ophthalmology, Kayseri City Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-9330-7965
Mehmet Fatih KücükDepartment of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID http://orcid.org/0000-0002-2548-7869
Muhammet Kazim ErolDepartment of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.ORCID http://orcid.org/0000-0002-1720-8065
Antalya Eğitim ve Araştırma Hastanesi · TRKayseri Eğitim ve Araştırma Hastanesi · TRSüleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the efficacy and refractive outcomes of intravitreal bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity (ROP) treatment.

methodsWe analyzed the files of patients treated with intravitreal bevacizumab, ranibizumab and aflibercept for ROP, retrospectively. A total of 187 eyes of 111 patients were included. Recurrence time after initial treatment, recurrence rate, age and rate of additional treatment, refractive outcomes in age 1, 2 and 3 were evaluated and compared between the groups.

resultsFifty-four eyes of 30 patients formed bevacizumab group (Group-1), 77 eyes of 47 patients formed ranibizumab group (Group-2) and 56 eyes of 34 patients formed aflibercept group (Group-3). No significant difference was found in gender, gestational age, birth weight and risk factors between the groups (p>0.05). Success rate was higher in group 3, but the difference was not significant (p = 0.174) (74.1% in group-1, 62.4% in group-2 and 76.8% in group-3). Recurrence rate was higher in group 2, but the difference was not significant (p = 0.158) (25.9% in group-1, 37.6% in group-2 and 23.2% in group-3). Recurrence time after initial treatment was significantly shorter in group 2 (p < 0.01). Additional treatment rate was also higher, and the age of additional treatment was lower in group-2 (p < 0.05 and p < 0.01, respectively). We found refractive values more myopic in ages of 1, 2 and 3 in group 1.

conclusionsBevacizumab, ranibizumab and aflibercept are effective treatment alternatives for ROP. We observed more frequent and much earlier recurrence in eyes treated with ranibizumab. A myopic shift was found in bevacizumab group. We also emphasize the necessity of longer follow-ups for infants treated with anti-VEGF drugs.

Indexed as

RanibizumabRetinopathy of PrematurityAngiogenesis InhibitorsBevacizumabHumansInfantInfant, NewbornIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityafliberceptAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptBevacizumabRanibizumabRetinopathy of prematurity

Identifiers

PMID35094229
OpenAlexW4210742259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.